Serum neurofilament light chain (sNfL) levels are associated with severe focal axonal damage, and baseline sNfL levels can predict long-term disease activity status in patients with multiple sclerosis (MS).
Why this matters
sNfL levels correlate with acute inflammation. However, whether it is possible to use sNfL levels to monitor neurodegenerative processes and predict progressive axonal damage in MS is unclear.
A better understanding of the correlation between sNfL and inflammation may help identify patients at greater risk of disability progression.